This HTML5 document contains 32 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n15https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
freebasehttp://rdf.freebase.com/ns/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Demethylating_agent
rdf:type
dbo:ChemicalCompound
rdfs:label
Demethylating agent
rdfs:comment
Demethylating agents are chemical substances that can inhibit methylation, resulting in the expression of the previously hypermethylated silenced genes (see Methylation#Cancer for more detail). Cytidine analogs such as 5-azacytidine (azacitidine) and 5-azadeoxycytidine (decitabine) are the most commonly used demethylating agents. They work by inhibiting DNA methyltransferases. Both compounds have been approved in the treatment of myelodysplastic syndrome (MDS) by Food and Drug Administration (FDA) in United States. Azacitidine and decitabine are marketed as Vidaza and Dacogen respectively. Azacitidine is the first drug to be approved by FDA for treating MDS and has been given orphan drug status. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. The
dcterms:subject
dbc:Biochemistry
dbo:wikiPageID
16818152
dbo:wikiPageRevisionID
1029263450
dbo:wikiPageWikiLink
dbr:Myelodysplastic_syndrome dbr:Food_and_Drug_Administration dbr:5-azacytidine dbr:Genes dbr:DNA_methyltransferase dbr:DsRNA dbr:Decitabine dbr:MDA5 dbr:Azacitidine dbr:Procaine dbr:Orphan_drug dbc:Biochemistry dbr:Cancer_stem_cell dbr:Mitochondrial_antiviral-signaling_protein dbr:Methylation dbr:Cytidine
owl:sameAs
freebase:m.0407b4z wikidata:Q5255196 n15:4igBg
dbp:wikiPageUsesTemplate
dbt:Biochemistry-stub dbt:Reflist
dbo:abstract
Demethylating agents are chemical substances that can inhibit methylation, resulting in the expression of the previously hypermethylated silenced genes (see Methylation#Cancer for more detail). Cytidine analogs such as 5-azacytidine (azacitidine) and 5-azadeoxycytidine (decitabine) are the most commonly used demethylating agents. They work by inhibiting DNA methyltransferases. Both compounds have been approved in the treatment of myelodysplastic syndrome (MDS) by Food and Drug Administration (FDA) in United States. Azacitidine and decitabine are marketed as Vidaza and Dacogen respectively. Azacitidine is the first drug to be approved by FDA for treating MDS and has been given orphan drug status. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. There are many other demethylating agents that can be used to inhibit the growth of other diseases.
gold:hypernym
dbr:Compounds
prov:wasDerivedFrom
wikipedia-en:Demethylating_agent?oldid=1029263450&ns=0
dbo:wikiPageLength
5886
foaf:isPrimaryTopicOf
wikipedia-en:Demethylating_agent